Biomarkers of Sensitivity to Potent and Selective Antitumor 2-(4-Amino-3-Methylphenyl)-5-Fluorobenzothiazole (5F203) in Ovarian Cancer

被引:23
作者
Callero, Mariana A. [1 ,2 ]
Luzzani, Gabriela A. [1 ]
De Dios, Diana O. [3 ]
Bradshaw, Tracey D. [4 ]
Loaiza Perez, Andrea I. [1 ,2 ]
机构
[1] Natl Sci Council CONICET, Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Res Area, Inst Oncol Angel H Roffo, Buenos Aires, DF, Argentina
[3] Univ Buenos Aires, Gynecol Oncol Dept, Inst Oncol Angel H Roffo, Buenos Aires, DF, Argentina
[4] Univ Nottingham, Ctr Biomol Sci, Nottingham NG7 2RD, England
关键词
AhR; CYP1A1; ROS; OVARIAN CANCER; 5F203; CARCINOMA CELLS; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; INDUCTION; POLYMORPHISMS; ASSOCIATION; DOXORUBICIN; EXPRESSION; RESISTANCE; MOLECULES;
D O I
10.1002/jcb.24589
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole (5F203, NSC 703786) lysylamide belongs to a novel mechanistic class of antitumor agents. It elicits activity against ovarian, breast, kidney and colorectal cancer models. In sensitive breast cancer cells, 5F203 activates aryl hydrocarbon receptor (AhR) signaling. Herein, we evaluate the role of AhR in 5F203 activity in two ovarian cancer cell lines: IGROV-1 (sensitive to 5F203), SKOV-3 (resistant to this agent). In addition, cancer cells have been isolated from ascites fluid of ovarian cancer patients; sensitivity to 5F203 and concurrent AhR signal transduction has been examined in ascites-isolated ovarian cancer patients' cells. 5F203 induced enhanced CYP1A1 expression, AhR translocation and ROS formation in IGROV-1 cells and ascites-isolated ovarian cancer cells that were sensitive to 5F203. In IGROV-1 cells 5F203-induced ROS formation was accompanied by JNK, ERK and P38MAPK phosphorylation, DNA damage and cell cycle arrest prior to apoptosis. In contrast, 5F203 failed to induce CYP1A1 expression, AhR translocation or oxidative stress in 5F203-resistant SKOV-3 cells, or in ovarian cancer ascites cells inherently resistant to this agent. We propose that AhR may represent a new molecular target in the treatment of ovarian tumors and 5F203 may exemplify a potential novel treatment. Furthermore, putative biomarkers of sensitivity to this agent have been identified. J. Cell. Biochem. 114: 2392-2404, 2013. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:2392 / 2404
页数:13
相关论文
共 38 条
[1]   2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor [J].
Bazzi, Rana ;
Bradshaw, Tracey D. ;
Rowlands, J. Craig ;
Stevens, Malcolm F. G. ;
Bell, David R. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2009, 237 (01) :102-110
[2]   CROSS-COUPLING OF SIGNAL TRANSDUCTION PATHWAYS - THE DIOXIN RECEPTOR MEDIATES INDUCTION OF CYTOCHROME P-450IA1 EXPRESSION VIA A PROTEIN KINASE-C-DEPENDENT MECHANISM [J].
BERGHARD, A ;
GRADIN, K ;
PONGRATZ, I ;
WHITELAW, M ;
POELLINGER, L .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :677-689
[3]  
Bradshaw TD, 2002, MOL CANCER THER, V1, P239
[4]   Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo [J].
Bradshaw, TD ;
Schultz, RJ ;
Paull, KD ;
Kelland, L ;
Wilson, A ;
Garner, C ;
Fiebig, HH ;
Wrigley, S ;
Stevens, MFG .
BRITISH JOURNAL OF CANCER, 1998, 78 (04) :421-429
[5]  
Bradshaw TD, 2000, MOL CANCER THER, V1, P239
[6]   Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines [J].
Bradshaw, Tracey D. ;
Stone, Erica L. ;
Trapani, Valentina ;
Leong, Chee-Onn ;
Matthews, Charles S. ;
Poele, Robert te ;
Stevens, Malcolm F. G. .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 110 (01) :57-68
[7]  
Cassinelli G, 2001, INT J CANCER, V92, P738, DOI 10.1002/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO
[8]  
2-2
[9]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[10]   The experimental antitumor agents Phortress and Doxorubicin are equiactive against human-derived breast carcinoma xenograft models [J].
Fichtner, I ;
Monks, A ;
Hose, C ;
Stevens, MFG ;
Bradshaw, TD .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 87 (01) :97-107